NCT01445535 2021-11-03Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell LymphomasNational Institutes of Health Clinical Center (CC)Phase 1 Completed15 enrolled 18 charts
NCT01116232 2019-03-26Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell TransplantationBarbara Ann Karmanos Cancer InstitutePhase 2 Terminated4 enrolled 4 charts